Cellosaurus BC-1 (CVCL_1079)

Cell line name BC-1
Synonyms BC1
Accession CVCL_1079
Resource Identification Initiative To cite this cell line use: BC-1 (RRID:CVCL_1079)
Comments Doubling time: ~35-48 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
Transformant: NCBI_TaxID; 37296; Human herpesvirus 8 (HHV-8/KSHV).
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: Transcriptome analysis.
Disease Primary effusion lymphoma (NCIt: C6915)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP; DSMZ

Markers:
AmelogeninX,Y
CSF1PO10,11
D13S3178
D16S53912,13
D5S81811,12
D7S82011
TH019.3
TPOX8,9
vWA16,20
Web pages http://www.cells-talk.com/index.php/page/copelibrary?key=BC-1
Publications

PubMed=7670109
Cesarman E., Moore P.S., Rao P.H., Inghirami G., Knowles D.M., Chang Y.
In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences.
Blood 86:2708-2714(1995)

PubMed=15613351; DOI=10.1128/JVI.79.2.1244-1251.2005
Fan W., Bubman D., Chadburn A., Harrington W.J. Jr., Cesarman E., Knowles D.M.
Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association.
J. Virol. 79:1244-1251(2005)

PubMed=21685375; DOI=10.1182/blood-2010-12-323659
Roy D., Sin S.-H., Damania B., Dittmer D.P.
Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines.
Blood 118:E32-E39(2011)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cross-references
Cell line collections ATCC; CRL-2230
DSMZ; ACC-677
Cell line databases/resources Cosmic-CLP; 910919
GDSC; 910919
IGRhCellID; BC1
LINCS_LDP; LCL-1956
Lonza; 914
Ontologies BTO; BTO:0002720
CLO; CLO_0001887
EFO; EFO_0002044
Biological sample resources BioSample; SAMN03471843
BioSample; SAMN03473432
BioSamples; SAMEA365796
BioSamples; SAMEA365808
Chemistry resources ChEMBL-Cells; CHEMBL3307907
ChEMBL-Targets; CHEMBL614277
Gene expression databases GEO; GSM38792
GEO; GSM38793
GEO; GSM634731
GEO; GSM710417
GEO; GSM710433
GEO; GSM1669610
Polymorphism and mutation databases Cosmic; 687602
Cosmic; 910919
Cosmic; 1515186
Cosmic; 1588556